Trasylol Patients and Clinical Trial Subjects Beware

Trasylol Patients and Clinical Trial Subjects Beware: "Thirteen years ago, the FDA approved Trasylol (aprotinin) for use in patients undergoing heart bypass surgery. In January 2006, doctors, consumer advocates and a medical research group called for the removal of the drug from the market after a study found it to have deadly side effects." [OpEdNews]